

On-line Table: Patient characteristics

Patient No.	Age, yr	Sex	Location	Size, mm	Dual-Antiplatelet Regimen	Complications	1st Follow-Up, mo	% Occlusion	2nd Follow-Up, mo	% Occlusion	Retreatment
1	61	F	L MCA	20.6	ASA 81 mg + ticagrelor 90 mg twice a day	No	5.7	>90	NA	NA	No
2	34	F	L ICAB	11.5	ASA 81 mg + ticagrelor 90 mg twice a day	No	6.5	<90	NA	NA	No
3	66	F	L PO	4.5	ASA 81 mg + ticagrelor 90 mg twice a day	No	4.3	<90	10.4	<90	No
4	71	M	L PO	6.6	ASA 325 mg + clopidogrel 75 mg	No	4.2	<90	11.0	<90	No
5			R PO	4.6	ASA 325 mg + clopidogrel 75 mg	No	6.8	<90	NA	NA	No
6	31	F	R PO	3.9	ASA 81 mg + ticagrelor 90 mg twice a day	No	4.2	<90	10.2	<90	2nd PED at 15.1 mo
7	55	F	R PO	6.1	ASA 325 mg + clopidogrel 75 mg	No	5.7	<90	NA	NA	No
8	62	F	R PCOMM	7.3	ASA 325 mg + clopidogrel 75 mg	No	6.3	<90	NA	NA	No
9	64	F	R PO	7.1	ASA 325 mg + clopidogrel 75 mg	No	5.4	<90	NA	NA	No
10 ^a	44	F	R PO	6.5	ASA 325 mg + clopidogrel 75 mg	No	6.0	<90	12.2	<90	2nd PED at 12.7 mo

Note:—ASA indicates acetylsalicylic acid; ICAB, internal carotid artery bifurcation; NA, not available; PCOMM, posterior communicating artery; PO, paraophthalmic artery.

^a Optical coherence tomography.